Telomir Pharmaceuticals Advisor to Join DIA 2024 Global Meeting Panel

Telomir Pharmaceuticals, Inc. (Nasdaq: TELO), a pioneering company in the pre-clinical stage specializing in the development and commercialization of Telomir-1, has announced that its scientific advisor, Dr. Adam Kaplin, will be a speaker at the DIA 2024 Global Annual Meeting on June 17, 2024. This event, hosted by the Drug Information Association (DIA), is the largest interdisciplinary gathering for professionals in pharmaceuticals, biotechnology, medical devices, and related sectors.

Dr. Kaplin's participation in this panel, organized by InSilicoTrials, will focus on the promising applications of generative AI in therapeutic studies. The discussion, entitled "Are Human Patients Needed for Clinical Trials, Tomorrow?" aims to explore the potential for AI-driven data modeling to significantly reduce both the time and cost associated with clinical trials while ensuring stringent patient safety standards are maintained. Dr. Kaplin expressed his enthusiasm about the opportunity to share his insights and learn from the experiences of other experts in the field. He emphasized that the use of generative AI technologies could dramatically enhance drug dosing, trial performance, and overall patient safety, potentially accelerating the market entry of new therapies by up to 90%.

Telomir Pharmaceuticals is dedicated to advancing Telomir-1, a groundbreaking small molecule intended to lengthen the protective telomere caps of DNA. This development is particularly significant in addressing age-related conditions. Telomeres, the protective ends of chromosomes, shorten as humans age, a process exacerbated by oxidative stress, increasing the risk of various degenerative diseases. Telomir’s goal is to offer Telomir-1, proposed for oral administration, as a treatment for a wide range of age-related inflammatory conditions, such as osteoarthritis.

The significance of telomeres in aging and disease was highlighted when the Nobel Prize in Physiology or Medicine was awarded in 2009 for the discovery of how telomeres and the enzyme telomerase protect chromosomes. This foundational work underpins Telomir’s research and development efforts.

InSilicoTrials, the organizer of the panel, seeks to revolutionize drug development through the use of computational modeling and simulation techniques. By leveraging AI and advanced predictive technologies, they aim to provide robust digital evidence and clinical outcomes, facilitating quicker and more cost-effective R&D processes. Their in silico methods include virtual patient trials and AI-enhanced accuracy in clinical assessments, contributing to more comprehensive and regulatory-compliant data to support clinical programs.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!